nvestor presentation 2019 First six months of 2019 Slide 4 n driven by: at CER of 2% at CER % at CER. Diabetes, Obesity, and Biopharmaceuticals grew 4%, as now been launched in 21 countries , along with two outcome trials (FLOW and FOCUS) and the oximately 15,000 people with type 2 diabetes 2 diabetes pe 2 diabetes in the US and received positive opinion from the hina 27.7 billion arnings per share decreased by 3% to DKK 8.39 d continued focus on cost control ound 3%-points higher than at CER) ported: around 5%-points higher than at CER) B share of DKK 0.20, which will be paid in August 2019 lar outcomes trials; FLOW: Semaglutide in chronic kidney disease; FOCUS: Semaglutide in diabetic retinopathy
Download PDF file